Personal Genome Diagnostics Inc.

Sell-side

Exclusive Financial Advisor, February 2022

Personal Genome Diagnostics Inc.
Sale to Labcorp (NYSE: LH)

Since its founding in 2010, PGDx has empowered the fight against cancer by unlocking actionable information from the genome to drive biomarker informed treatment plans. The PGDx elio™ portfolio of tissue-based and liquid biopsy comprehensive genomic solutions enable personalized care for all patients by bringing precision oncology testing to where they are. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >